Immunoprecise Antibodies Ltd(IPA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IPA Immunoprecise Antibodies Ltd

Market Closed 10-04 16:00:00 EDT

0.6250

+0.0825

+15.21%

盘后0.6300

+0.0050+0.80%

18:03 EDT

High0.6300	Low0.5500	Vol603.21K
Open0.5500	D1 Closing0.5425	Amplitude14.75%
Mkt Cap17.45M	Tradable Cap15.27M	Total Shares27.92M
T/O357.83K	T/O Rate2.47%	Tradable Shares24.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IPA","market":"US","secType":"STK","nameCN":"Immunoprecise Antibodies Ltd","latestPrice":0.625,"timestamp":1728072000000,"preClose":0.5425,"halted":0,"volume":603206,"hourTrading":{"tag":"盘后","latestPrice":0.63,"preClose":0.625,"latestTime":"18:03 EDT","volume":1203,"amount":756.6446,"timestamp":1728079390547},"delay":0,"floatShares":24429876,"shares":27915561,"eps":-0.768333,"marketStatus":"Market Closed","change":0.0825,"latestTime":"10-04 16:00:00 EDT","open":0.55,"high":0.63,"low":0.55,"amount":357829.640878,"amplitude":0.147465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.768333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1728288000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.5425,"preHourTrading":{"tag":"盘前","latestPrice":0.5683,"preClose":0.535,"latestTime":"08:00 EDT","volume":10,"amount":5.683,"timestamp":1728043207537},"postHourTrading":{"tag":"盘后","latestPrice":0.63,"preClose":0.625,"latestTime":"18:03 EDT","volume":1203,"amount":756.6446,"timestamp":1728079390547},"volumeRatio":1.2344477906380498,"impliedVol":1.0458,"impliedVolPercentile":0.2659},"requestUrl":"/m/hq/s/IPA/tweets","defaultTab":"tweets","newsList":[{"id":"2472544505","title":"Immunoprecise Subsidiary Signs Material Transfer Agreement With Biotheus","url":"https://stock-news.laohu8.com/highlight/detail?id=2472544505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472544505?lang=en_us&edition=fundamental","pubTime":"2024-10-02 20:00","pubTimestamp":1727870402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nTUA4SY7B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2472441495","title":"Immunoprecise Antibodies Ltd - Biotheus to Evaluate Talem's AI-Enhanced Tatx-20 for Bispecific Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2472441495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472441495?lang=en_us&edition=fundamental","pubTime":"2024-10-02 20:00","pubTimestamp":1727870402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nTUA4SY7B2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IPA","BK4121"],"gpt_icon":0},{"id":"2472179544","title":"Immunoprecise Antibodies Ltd: Talem Therapeutics' Antibody Asset to Be Evaluated for Bispecific Development Against Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2472179544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472179544?lang=en_us&edition=fundamental","pubTime":"2024-10-02 20:00","pubTimestamp":1727870402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nTUA4SY7B2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2472547302","title":"ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus","url":"https://stock-news.laohu8.com/highlight/detail?id=2472547302","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472547302?lang=en_us&edition=fundamental","pubTime":"2024-10-02 20:00","pubTimestamp":1727870400,"startTime":"0","endTime":"0","summary":"Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors. Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, stated: \"We're excited to transfer our AI-enhanced therapeutic antibody asset to Biotheus for bispecific molecule development. This strategic move leverages our cutting-edge technology in antibody discovery and Biotheus' expertise in bispecific engineering. Our collaboration aims to accelerate the creation of innovative cancer treatments, potentially leading to groundbreaking clinical outcomes. This agreement not only demonstrates the value of our AI-enhanced assets but also sets the stage for a long-term, mutually beneficial partnership that could transform the landscape of cancer therapeutics. We anticipate this collaborati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/19f34OTed1G_RcEIbGOzRw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/df04336205902bc5b57373b5e91a1be7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/19f34OTed1G_RcEIbGOzRw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/df04336205902bc5b57373b5e91a1be7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunoprecise-subsidiary-signs-material-transfer-120000043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2472630707","title":"Marcus & Millichap’s Institutional Property Advisors Brokers Sale of Grocery-Anchored Regional Power Center in Central New Jersey","url":"https://stock-news.laohu8.com/highlight/detail?id=2472630707","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472630707?lang=en_us&edition=fundamental","pubTime":"2024-10-02 01:50","pubTimestamp":1727805000,"startTime":"0","endTime":"0","summary":"HAMILTON TOWNSHIP, N.J., October 01, 2024----Institutional Property Advisors , a division of Marcus & Millichap , announced the sale of Hamilton Marketplace, a grocery-anchored regional power center in Hamilton Township, New Jersey. The center sold for a total consideration of over $100 million, making it the largest single-asset open-air shopping center transaction to close in New Jersey since 2017.\"On the open market for the first time since development, the offering drew a pool of private and institutional capital that we haven’t seen since before the pandemic and interest from large private family offices that know the value of controlling over 128 acres with highway frontage,\" said Brad Nathanson, IPA executive director. \"Best-of-class power centers have had some of the strongest resiliency and rent appreciation in the product type since 2021, given the lack of new construction and high re-tenanting cost that appreciated rents at an above average rate. This created a demand driver","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Glhm..eKuhgaKDib2wJWhA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/028eeec86e011f61289ace8a98daa5ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Glhm..eKuhgaKDib2wJWhA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/028eeec86e011f61289ace8a98daa5ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/marcus-millichap-institutional-property-advisors-175000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4079","IE00B19Z6F94.USD","MMI","BK4121","IPA","BK4084","PW","BK4234","IE0034390439.USD"],"gpt_icon":0},{"id":"2470734611","title":"ImmunoPrecise’s Breakthroughs in Cancer Antibody Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2470734611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470734611?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:27","pubTimestamp":1727357232,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies (IPA) has released an update. ImmunoPrecise Antibodies Ltd. (IPA) is making significant strides in cancer treatment with t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunoprecises-breakthroughs-in-cancer-antibody-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunoprecises-breakthroughs-in-cancer-antibody-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPA","BK4121"],"gpt_icon":0},{"id":"2470366327","title":"BRIEF-Immunoprecise Antibodies Advances Therapeutic Innovation With Groundbreaking Rabbit Antibody Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2470366327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470366327?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:04","pubTimestamp":1727355885,"startTime":"0","endTime":"0","summary":"Sept 26 (Reuters) - Immunoprecise Antibodies Ltd :   * IMMUNOPRECISE ANTIBODIES ADVANCES THERAPEUTIC INNOVATION WITH GROUNDBREAKING RABBIT ANTIBODY DEVELOPMENTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPA","BK4121"],"gpt_icon":0},{"id":"2470363267","title":"Immunoprecise Antibodies Advances Therapeutic Innovation With Groundbreaking Rabbit Antibody Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2470363267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470363267?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:03","pubTimestamp":1727355781,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nFWN3L8133:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2470736207","title":"ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2470736207","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470736207?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:00","pubTimestamp":1727355600,"startTime":"0","endTime":"0","summary":"Rabbit B Cell Select Drives Clinical Breakthroughs in Cancer Treatment. VICTORIA, British Columbia, September 26, 2024----ImmunoPrecise Antibodies Ltd.  , ImmunoPrecise Antibodies Ltd.  , an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA’s proprietary B Cell Select platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPA’s leadership as a Contract Research Organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. These antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes.\"At ImmunoPrecise Antibodies, our mission is not just to develop antibodies, but to redefine what’s possible in therapeutic interventions,\" said Dr. Jenn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uL1wpuY9z7i5jGdYHhngtA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7ab75e66e5d9be534ec8ec4518da6fa5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uL1wpuY9z7i5jGdYHhngtA--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7ab75e66e5d9be534ec8ec4518da6fa5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunoprecise-antibodies-advances-therapeutic-innovation-130000247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4509","LU0359201612.USD","LU2039709279.SGD","BK4571","BK4121","IE00B12V2V27.USD","01698","LU1023057109.AUD","BK4563","IE00BYTNYN87.SGD","SG9999011746.SGD","IE00BYQNZ168.SGD","BK4108","BK4531","BK4526","CPI","BK4548","LU0359202008.SGD","BK4535","BK4552","IPA","BK4565"],"gpt_icon":1},{"id":"2470821801","title":"Press Release: Institute for Portfolio Alternatives Announces 2025 Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2470821801","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470821801?lang=en_us&edition=fundamental","pubTime":"2024-09-26 04:22","pubTimestamp":1727295720,"startTime":"0","endTime":"0","summary":"Jason Goode, Alston & Bird, Elected Incoming Chair. WASHINGTON, Sept. 25, 2024 /PRNewswire/ -- Anya Coverman, President & CEO of the Institute for Portfolio Alternatives , today announced the organization's Board of Directors for 2025. Newly elected board members will serve a three-year term, beginning on January 1, 2025.\"As we look forward to the year ahead, I am excited to collaborate with this outstanding Board of Directors to advance policies that drive innovation and growth in the alternative investment industry, while promoting expanded opportunities for investors,\" said Coverman. \"Our newly elected directors represent some of the leading firms throughout this growing and vibrant financial sector, and we look forward to having their perspectives on the IPA's Board of Directors.\". Bill Duffy, Vice President of Alternative Investments at Fidelity Investments, will lead the Board as chair in 2025.Newly elected members of the 2025 IPA Board of Directors are:. They will join continuin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1363072403.SGD","LU0225283273.USD","BK4581","LU0314104364.USD","IPA","LU0971096721.USD","BK4585","LU1720051017.SGD","BK4127","LU1720051108.HKD","LU1989772840.SGD","LU1989772923.USD","BK4504","LU1162221912.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU0267386448.USD","LU1074936037.SGD","LU2357305700.SGD","BK4588","LU1668664300.SGD","LU0320765646.SGD","BK4121","LU1548497426.USD"],"gpt_icon":0},{"id":"2469219781","title":"ImmunoPrecise Sets Virtual Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2469219781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469219781?lang=en_us&edition=fundamental","pubTime":"2024-09-24 02:57","pubTimestamp":1727117831,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies (IPA) has released an update. ImmunoPrecise Antibodies Ltd. has announced its upcoming Annual General and Special Meeting,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunoprecise-sets-virtual-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunoprecise-sets-virtual-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPA","BK4121"],"gpt_icon":0},{"id":"2468726636","title":"Marcus & Millichap’s IPA Capital Markets Arranges $75 Million Financing for Midtown Manhattan Office-to-Residential Conversion Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2468726636","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468726636?lang=en_us&edition=fundamental","pubTime":"2024-09-20 05:15","pubTimestamp":1726780500,"startTime":"0","endTime":"0","summary":"NEW YORK, September 19, 2024----IPA Capital Markets, a division of Marcus & Millichap , specializing in capital markets services for major private and institutional clients, has secured $75 million in acquisition financing for the former Pfizer headquarters in New York City. Located at 219 E 42nd St., the property will be combined with the adjacent building at 235 E 42nd St. and converted into a free-market, Class-A, luxury multifamily apartment building.\"When these two buildings are combined, it will add more than 800 units to the project totaling to over 1,400 units, making it the largest office-to-residential conversion in New York City’s history,\" said Max Herzog, IPA Capital Markets.The New York-based IPA Capital Markets team of Herzog, Marko Kazanjian, Andrew Cohen and Max Hulsh secured the financing with Northwind Group on behalf of David Werner Real Estate Investments and Metro Loft Management.Located in Midtown East, the property will be converted from a 10-story, 291,000-gros","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBboMEVRuiEy_33aV8WF8g--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c1a591efd94b13d48f13b7d9cd30abd6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBboMEVRuiEy_33aV8WF8g--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c1a591efd94b13d48f13b7d9cd30abd6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/marcus-millichap-ipa-capital-markets-211500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4079","MMI","IPA","IE0034390439.USD","IE00B19Z6F94.USD","BK4121"],"gpt_icon":0},{"id":"2468353418","title":"ImmunoPrecise Antibodies Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2468353418","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468353418?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:48","pubTimestamp":1726573680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 17, 2024 07:48 ET (11:48 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPA"],"gpt_icon":0},{"id":"2467843564","title":"ImmunoPrecise Achieves AI-Driven Growth Amidst Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2467843564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467843564?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:27","pubTimestamp":1726493257,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies (IPA) has released an update. ImmunoPrecise Antibodies Ltd. (IPA) has reported a first-quarter revenue of $5.3 million for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunoprecise-achieves-ai-driven-growth-amidst-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunoprecise-achieves-ai-driven-growth-amidst-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2467843596","title":"ImmunoPrecise Advances Biotherapeutic Research Efficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2467843596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467843596?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:27","pubTimestamp":1726493246,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies (IPA) has released an update. ImmunoPrecise Antibodies Ltd. (IPA), a leader in biotherapeutic research and technology, has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunoprecise-advances-biotherapeutic-research-efficiency?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunoprecise-advances-biotherapeutic-research-efficiency?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2467848227","title":"ImmunoPrecise GAAP EPS of -C$0.15, revenue of C$5.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2467848227","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467848227?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:06","pubTimestamp":1726491962,"startTime":"0","endTime":"0","summary":"ImmunoPrecise press release  (NASDAQ:IPA): Q1  GAAP EPS of -C$0.15.\nRevenue of C$5.3M (-7.0% Y/Y).\nCash totaled C$4.0 million as of July 31, 2024, compared to C$6.8 million as of July 31, 2023.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4149951-immunoprecise-gaap-eps-of--c015-revenue-of-c53m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QID","MNQmain","IPA",".IXIC","NQmain","SQQQ","TQQQ","BK4121","QLD","PSQ"],"gpt_icon":0},{"id":"2467917810","title":"ImmunoPrecise Antibodies Q1 2025 GAAP EPS $(0.15) Misses $(0.13) Estimate, Sales $5.300M Miss $6.750M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2467917810","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467917810?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:02","pubTimestamp":1726491741,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent.  The company reported quarterly sales of $5.300 million which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40877834/immunoprecise-antibodies-q1-2025-gaap-eps-0-15-misses-0-13-estimate-sales-5-300m-miss-6-750m-estima","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ImmunoPrecise Antibodies Q1 2025 GAAP EPS $(0.15) Misses $(0.13) Estimate, Sales $5.300M Miss $6.750M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPA"],"gpt_icon":0},{"id":"2467394810","title":"Immunoprecise Antibodies (Ipa) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2467394810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467394810?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:00","pubTimestamp":1726491604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nTUA6GG7ZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","IPA"],"gpt_icon":0},{"id":"2467810809","title":"Immunoprecise Antibodies Q1 Revenue CAD 5.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2467810809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467810809?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:00","pubTimestamp":1726491603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nPLX98B1E9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IPA","BK4121"],"gpt_icon":0},{"id":"2467810570","title":"Press Release: ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2467810570","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467810570?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:00","pubTimestamp":1726491600,"startTime":"0","endTime":"0","summary":"ImmunoPrecise Antibodies  Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025. Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENS. IMMUNOPRECISE ANTIBODIES LTD.  , an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year , which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted.BioStrand is driving revenue growth through its LENS platform, offering fee-for-service solutions while developing commercial products tailored to IPA's extensive client base of over 600 companies. Recently, BioStrand","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4571","R","LU1023057109.AUD","BK4022","BK4531","BK4548","BK4232","LU0359202008.SGD","SG9999011746.SGD","IE00BYQNZ168.SGD","BK4121","BK4509","BK4108","BK4526","BK4565","BK4563","LU2039709279.SGD","TME","IE00BYTNYN87.SGD","BK4535","IPA","IE00B12V2V27.USD","LU0359201612.USD","BK4552","01698"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunoprecise.com","stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.0958},{"period":"3month","weight":-0.375},{"period":"6month","weight":-0.566},{"period":"1year","weight":-0.6166},{"period":"ytd","weight":-0.6345}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.04},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.3498},{"period":"ytd","weight":0.2055}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.04828},{"month":2,"riseRate":0.25,"avgChangeRate":-0.118539},{"month":3,"riseRate":0.25,"avgChangeRate":-0.179314},{"month":4,"riseRate":0.25,"avgChangeRate":-0.038624},{"month":5,"riseRate":0.5,"avgChangeRate":-0.017976},{"month":6,"riseRate":0,"avgChangeRate":-0.179973},{"month":7,"riseRate":0.5,"avgChangeRate":-0.04032},{"month":8,"riseRate":0.5,"avgChangeRate":0.022134},{"month":9,"riseRate":0,"avgChangeRate":-0.148494},{"month":10,"riseRate":0.75,"avgChangeRate":0.134693},{"month":11,"riseRate":0,"avgChangeRate":-0.137051},{"month":12,"riseRate":0.666667,"avgChangeRate":0.012351}],"exchange":"NASDAQ","name":"Immunoprecise Antibodies Ltd","nameEN":"Immunoprecise Antibodies Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunoprecise Antibodies Ltd(IPA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunoprecise Antibodies Ltd(IPA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunoprecise Antibodies Ltd,IPA,Immunoprecise Antibodies Ltd股票,Immunoprecise Antibodies Ltd股票老虎,Immunoprecise Antibodies Ltd股票老虎国际,Immunoprecise Antibodies Ltd行情,Immunoprecise Antibodies Ltd股票行情,Immunoprecise Antibodies Ltd股价,Immunoprecise Antibodies Ltd股市,Immunoprecise Antibodies Ltd股票价格,Immunoprecise Antibodies Ltd股票交易,Immunoprecise Antibodies Ltd股票购买,Immunoprecise Antibodies Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunoprecise Antibodies Ltd(IPA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunoprecise Antibodies Ltd(IPA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}